Span­ish VC preps launch for €100M fund with an em­pha­sis on ad­vanced ther­a­pies

Last year
Financing

Sen. War­ren at­tacks GSK's de­ci­sion to shift in­haler from brand to au­tho­rized gener­ic

Last year
Pharma
Law

Eu­ro­pean Com­mis­sion spells out new pro­pos­als for health tech­nol­o­gy as­sess­ments

Last year
Pharma
FDA+

Pfiz­er says IRA im­pact will be 'mod­est,' maps out R&D pri­or­i­ty changes

Last year
Pharma

San­doz wins FDA ap­proval for first two biosim­i­lars for Am­gen's block­buster bone drug

Last year
Pharma
FDA+

UK's NICE rec­om­mends against cov­er­age for As­traZeneca and Dai­ichi's breast can­cer drug En­her­tu over ...

Last year
Pharma

J&J ex­pands myelo­ma and health eq­ui­ty ef­forts with fe­male hip-hop pi­o­neer MC Lyte

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er jumps on lat­est Tik­Tok trend; No­vo re­cruits for Ca­griSe­ma tri­al across lan­guages

Last year
Pharma
Marketing

FDA de­nies hear­ing to Van­da on jet lag in­di­ca­tion for sleep dis­or­der drug

Last year
Pharma
FDA+

Re­genxbio gives glimpse at ear­ly Duchenne gene ther­a­py re­sults, plans piv­otal study for ac­cel­er­at­ed ap­proval

Last year
R&D
Cell/Gene Tx

Roche, Al­ny­lam’s zilebe­sir­an suc­ceeds in an­oth­er PhII hy­per­ten­sion test

Last year
R&D

Bridge­Bio's $250M of­fer­ing; Vi­iV's PhI da­ta for ul­tra-long-act­ing HIV treat­ment

Last year
News Briefing

Amy­lyx read­ies for make-or-break PhI­II, look­ing to ad­dress un­cer­tain­ty over con­tro­ver­sial ALS drug

Last year
R&D
Pharma

How Ap­ple’s vice pres­i­dent of health views op­por­tu­ni­ties in health­care

Last year
Health Tech

Bay­er on job cuts, pipeline gaps, obe­si­ty and Mon­san­to lit­i­ga­tion as ex­ecs de­fend keep­ing cur­rent struc­ture

Last year
R&D
Pharma

Q&A: Ken Song de­tails Rayze­Bio’s path from Se­ries A to IPO in 3 years, tak­ing a down round and be­ing dis­ci­plined

Last year
People

Aus­tralian bio­phar­ma buys ra­dioiso­tope pro­duc­er in its next step to ‘dou­ble’ ca­pac­i­ty in 2024 

Last year
Deals
Manufacturing

No­vo’s kid­ney dis­ease win for Ozem­pic adds to case for ex­pand­ed use in di­a­bet­ic pa­tients

Last year
R&D

Swedish biotech un­veils topline da­ta on weight loss drug de­signed for main­te­nance af­ter GLP-1s

Last year
R&D

Bay­er says no breakup ‘for now,’ fo­cus­es in­stead on fix­ing ‘bad­ly bro­ken’ ar­eas 

Last year
Pharma

Re­pub­li­can sen­a­tors join at­tack on Biden's pro­pos­al to seize drug patents based on price

Last year
Pharma
Law

FTC's Lina Khan and Mark Cuban head­line White House lis­ten­ing ses­sion to rail against PBMs

Last year
Pharma

Hugel smooths out wrin­kles with FDA, wins ap­proval for Botox com­peti­tor

Last year
Pharma
FDA+

San­doz com­pletes $170M buy of Lu­cen­tis biosim­i­lar from Co­herus Bio­Sciences

Last year
Deals
Pharma
First page Previous page 190191192193194195196 Next page Last page
A service from the Financial Times